Market News

Stay updated with the latest market trends, earnings, and economic indicators.

Showing news for:MOLOWVOLHealthcare
Clear all filters
Buy Glenmark Pharma; target of Rs 2610: Motilal Oswal
positive
Moneycontrol NaNd ago

Buy Glenmark Pharma; target of Rs 2610: Motilal Oswal

Motilal Oswal is bullish on Glenmark Pharma recommended buy rating on the stock with a target price of Rs 2610 in its research report dated June 01, 2026.

GLENMARKMOALPHA50MOBANK10MOCAPITALMODEFENCEMOENERGYMOGOLDMOGSECMOHEALTHMOINFRAMOIPOMOLOWVOLMOM100MOM50MOMENTUM50MOMGFMOMIDMTMMOMNCMOMOMENTUMMON100MON50EQUALMONEXT50MONIFTY100MONIFTY500MONQ50MOPSEMOQUALITYMOREALTYMOSERVICEMOSILVERMOSMALL250MOTILALOFSMOTOURMOVALUESPARCFinancial ServicesHealthcare
Buy Dr Agarwals Health Care; target of Rs 610: Motilal Oswal
positive
Moneycontrol NaNd ago

Buy Dr Agarwals Health Care; target of Rs 610: Motilal Oswal

Motilal Oswal is bullish on Dr Agarwals Health Care recommended buy rating on the stock with a target price of Rs 610 in its research report dated Jun 05, 2026.

AGARWALEYEAMRUTANJANMEDANTAMOALPHA50MOBANK10MOCAPITALMODEFENCEMOENERGYMOGOLDMOGSECMOHEALTHMOINFRAMOIPOMOLOWVOLMOM100MOM50MOMENTUM50MOMGFMOMIDMTMMOMNCMOMOMENTUMMON100MON50EQUALMONEXT50MONIFTY100MONIFTY500MONQ50MOPSEMOQUALITYMOREALTYMOSERVICEMOSILVERMOSMALL250MOTILALOFSMOTOURMOVALUEPGHHZOTAFast Moving Consumer GoodsFinancial Services
Buy Ipca Laboratories; target of Rs 1730: Motilal Oswal
positive
Moneycontrol NaNd ago

Buy Ipca Laboratories; target of Rs 1730: Motilal Oswal

Motilal Oswal is bullish on Ipca Laboratories recommended buy rating on the stock with a target price of Rs 1730 in its research report dated June 01, 2026.

IPCALABMOALPHA50MOBANK10MOCAPITALMODEFENCEMOENERGYMOGOLDMOGSECMOHEALTHMOINFRAMOIPOMOLOWVOLMOM100MOM50MOMENTUM50MOMGFMOMIDMTMMOMNCMOMOMENTUMMON100MON50EQUALMONEXT50MONIFTY100MONIFTY500MONQ50MOPSEMOQUALITYMOREALTYMOSERVICEMOSILVERMOSMALL250MOTILALOFSMOTOURMOVALUEFinancial ServicesHealthcare
Buy Rubicon Research; target of Rs 1160: Motilal Oswal
positive
Moneycontrol NaNd ago

Buy Rubicon Research; target of Rs 1160: Motilal Oswal

Motilal Oswal is bullish on Rubicon Research recommended buy rating on the stock with a target price of Rs 1160 in its research report dated May 30, 2026.

MOALPHA50MOBANK10MOCAPITALMODEFENCEMOENERGYMOGOLDMOGSECMOHEALTHMOINFRAMOIPOMOLOWVOLMOM100MOM50MOMENTUM50MOMGFMOMIDMTMMOMNCMOMOMENTUMMON100MON50EQUALMONEXT50MONIFTY100MONIFTY500MONQ50MOPSEMOQUALITYMOREALTYMOSERVICEMOSILVERMOSMALL250MOTILALOFSMOTOURMOVALUERUBICONFinancial ServicesHealthcare
Neutral ALKEM Laboratories; target of Rs 5840: Motilal Oswal
positive
Moneycontrol NaNd ago

Neutral ALKEM Laboratories; target of Rs 5840: Motilal Oswal

Motilal Oswal recommended Neutral rating on ALKEM Laboratories with a target price of Rs 5840 in its research report dated May 28, 2026.

ALKEMMOALPHA50MOBANK10MOCAPITALMODEFENCEMOENERGYMOGOLDMOGSECMOHEALTHMOINFRAMOIPOMOLOWVOLMOM100MOM50MOMENTUM50MOMGFMOMIDMTMMOMNCMOMOMENTUMMON100MON50EQUALMONEXT50MONIFTY100MONIFTY500MONQ50MOPSEMOQUALITYMOREALTYMOSERVICEMOSILVERMOSMALL250MOTILALOFSMOTOURMOVALUEFinancial ServicesHealthcare
SBI MF, Nippon India MF buy Rs 272 crore worth Pine Labs shares; ICICI Pru MF acquire 1.5% stake in Indoco Remedies
positive
Moneycontrol NaNd ago

SBI MF, Nippon India MF buy Rs 272 crore worth Pine Labs shares; ICICI Pru MF acquire 1.5% stake in Indoco Remedies

SBI Mutual Fund through SBI Midcap Fund held 5.24 percent stake in Pine Labs, the point of sale and payment systems provider, as of March 2026.

ABSLPSEALPHAALPHAETFAONEGOLDAONELIQUIDAONENIFTYAONESILVERAONETOTALAUTOBEESAUTOIETFAXISBPSETFBANK10ADDBANKADDBANKBETFBANKETFBANKPSUBBETF0432BBNPNBETFBBNPPGOLDBFSIBNKETFAXISCHEMICALCHOICEGOLDCOMMOIETFCONSUMAXISDEFENCEDIVIDENDEBANKNIFTYEBBETF0430EBBETF0431EBBETF0433ECAPINSUREEGOLDELIQUIDELM250ENERGYENIFTYEQUAL200EQUAL50EQUAL50ADDESENSEXESGESILVERFINIETFFLEXIADDFMCGADDFMCGIETFGILT10BETAGILT5BETAGOLD1GOLD360GOLDADDGOLDAXISGOLDBETAGOLDBNDGOLDETFGROWWCAPMGROWWCHEMGROWWDEFNCGROWWEVGROWWGOLDGROWWHOSPIGROWWLIQIDGROWWLOVOLGROWWMC150GROWWMETALGROWWMOM50GROWWN200GROWWNETGROWWNIFTYGROWWNXT50GROWWPOWERGROWWPSEGROWWPSUBKGROWWRAILGROWWRLTYGROWWSC250GROWWSLVRGSEC10IETFGSEC10YEARHDFCGOLDHDFCGROWTHHDFCLOWVOLHDFCMID150HDFCMOMENTHDFCNEXT50HDFCNIF100HDFCNIFITHDFCPSUBKHDFCPVTBANHDFCQUALHDFCSILVERHDFCSML250HDFCVALUEHEALTHADDHEALTHAXISHEALTHCAREHEALTHIETFHSBCGOLDICICIB22INDOCOINFRAIETFINTERNETITADDITAXISITBEESITBETAITETFITIETFLICNETFSENLICNMID100LIQGRWBEESLIQUIDLIQUID1LIQUIDPLUSLIQUIDSBILIQUIDSHRILOWVOLMAFANGMAHKTECHMAKEINDIAMANUFGBEESMASPTOP50METALMETALIETFMID150MID150BEESMID150CASEMIDCAPMIDCAPADDMIDCAPBETAMIDCAPETFMIDCAPIETFMIDQ50ADDMIDSELIETFMNCMOALPHA50MOBANK10MOCAPITALMODEFENCEMOENERGYMOGOLDMOGSECMOHEALTHMOINFRAMOIPOMOLOWVOLMOM100MOM30IETFMOM50MOMENTUMMOMENTUM30MOMENTUM50MOMGFMOMIDMTMMOMNCMOMOMENTUMMON100MON50EQUALMONEXT50MONIFTY100MONIFTY500MONQ50MOPSEMOQUALITYMOREALTYMOSERVICEMOSILVERMOSMALL250MOTOURMOVALUEMSCIADDMSCIINDIAMULTICAPNEXT30ADDNEXT50NEXT50ADDNEXT50BETANEXT50ETFNEXT50IETFNIFTY100EWNIFTYADDNIFTYAXISNIFTYBETFNIFTYETFNIFTYQLITYOILIETFPHARMABEESPINELABSPSUBANKADDPSUBNKIETFPVTBANKADDQUALITY30RSYSTEMSSBIBPBSBICARDSBIETFCONSBIETFITSBIETFPBSBIETFQLTYSBILIQETFSBINEQWETFSBINMID150SBISILVERSDL26BEESSELECTIPOSENSEXAXISSENSEXETFSETF10GILTSILVERSILVER1SILVER360SILVERADDSILVERAGSILVERAXISSILVERBEESSILVERBETASILVERBNDSILVERIETFSMALL250SMALLADDSNXT30BEESTATAGOLDTATSILVTECHTNIDETFTOP10ADDTOP20TWCGOLDETFUNIONGOLDVAL30IETFVALUEVALUEAXISFinancial ServicesHealthcare
Neutral Lupin; target of Rs 2520: Motilal Oswal
positive
Moneycontrol NaNd ago

Neutral Lupin; target of Rs 2520: Motilal Oswal

Motilal Oswal recommended Neutral rating on Lupin with a target price of Rs 2520 in its research report dated May 10, 2026.

LUPINMOALPHA50MOBANK10MOCAPITALMODEFENCEMOENERGYMOGOLDMOGSECMOHEALTHMOINFRAMOIPOMOLOWVOLMOM100MOM50MOMENTUM50MOMGFMOMIDMTMMOMNCMOMOMENTUMMON100MON50EQUALMONEXT50MONIFTY100MONIFTY500MONQ50MOPSEMOQUALITYMOREALTYMOSERVICEMOSILVERMOSMALL250MOTILALOFSMOTOURMOVALUEFinancial ServicesHealthcare
Max Healthcare shares fall up to 7% as Q4 results miss estimates
neutral
Moneycontrol NaNd ago

Max Healthcare shares fall up to 7% as Q4 results miss estimates

Analysts at domestic brokerage Motilal Oswal Financial Services said the earnings miss was due to a higher tax rate .

HCGHCG-REHEALTHCAREJMFINANCILMAXHEALTHMAXINDMFSLMOALPHA50MOBANK10MOCAPITALMODEFENCEMOENERGYMOGOLDMOGSECMOHEALTHMOINFRAMOIPOMOLOWVOLMOM100MOM50MOMENTUM50MOMGFMOMIDMTMMOMNCMOMOMENTUMMON100MON50EQUALMONEXT50MONIFTY100MONIFTY500MONQ50MOPSEMOQUALITYMOREALTYMOSERVICEMOSILVERMOSMALL250MOTILALOFSMOTOURMOVALUEFinancial ServicesHealthcare
Neutral Zydus LifeSciences; target of Rs 1080: Motilal Oswal
positive
Moneycontrol NaNd ago

Neutral Zydus LifeSciences; target of Rs 1080: Motilal Oswal

Motilal Oswal recommended Neutral rating on Zydus LifeSciences with a target price of Rs 1080 in its research report dated May 20, 2026.

MOALPHA50MOBANK10MOCAPITALMODEFENCEMOENERGYMOGOLDMOGSECMOHEALTHMOINFRAMOIPOMOLOWVOLMOM100MOM50MOMENTUM50MOMGFMOMIDMTMMOMNCMOMOMENTUMMON100MON50EQUALMONEXT50MONIFTY100MONIFTY500MONQ50MOPSEMOQUALITYMOREALTYMOSERVICEMOSILVERMOSMALL250MOTILALOFSMOTOURMOVALUEZYDUSLIFEFinancial ServicesHealthcare
Neutral Blue Star; target of Rs 1920: Motilal Oswal
positive
Moneycontrol NaNd ago

Neutral Blue Star; target of Rs 1920: Motilal Oswal

Motilal Oswal recommended Neutral rating on Blue Star with a target price of Rs 1920 in its research report dated May 07, 2026.

BLUESTARCOMOALPHA50MOBANK10MOCAPITALMODEFENCEMOENERGYMOGOLDMOGSECMOHEALTHMOINFRAMOIPOMOLOWVOLMOM100MOM50MOMENTUM50MOMGFMOMIDMTMMOMNCMOMOMENTUMMON100MON50EQUALMONEXT50MONIFTY100MONIFTY500MONQ50MOPSEMOQUALITYMOREALTYMOSERVICEMOSILVERMOSMALL250MOTILALOFSMOTOURMOVALUESTARConsumer DurablesFinancial Services
Buy Ajanta Pharma; target of Rs 3400: Motilal Oswal
positive
Moneycontrol NaNd ago

Buy Ajanta Pharma; target of Rs 3400: Motilal Oswal

Motilal Oswal is bullish on Ajanta Pharma has recommended buy rating on the stock with a target price of Rs 3400 in its research report dated May 05, 2026.

AJANTPHARMMOALPHA50MOBANK10MOCAPITALMODEFENCEMOENERGYMOGOLDMOGSECMOHEALTHMOINFRAMOIPOMOLOWVOLMOM100MOM50MOMENTUM50MOMGFMOMIDMTMMOMNCMOMOMENTUMMON100MON50EQUALMONEXT50MONIFTY100MONIFTY500MONQ50MOPSEMOQUALITYMOREALTYMOSERVICEMOSILVERMOSMALL250MOTILALOFSMOTOURMOVALUESPARCFinancial ServicesHealthcare
Buy Laurus Labs; target of Rs 1370: Motilal Oswal
positive
Moneycontrol NaNd ago

Buy Laurus Labs; target of Rs 1370: Motilal Oswal

Motilal Oswal is bullish on Laurus Labs has recommended buy rating on the stock with a target price of Rs 1370 in its research report dated April 30, 2026.

LAURUSLABSMOALPHA50MOBANK10MOCAPITALMODEFENCEMOENERGYMOGOLDMOGSECMOHEALTHMOINFRAMOIPOMOLOWVOLMOM100MOM50MOMENTUM50MOMGFMOMIDMTMMOMNCMOMOMENTUMMON100MON50EQUALMONEXT50MONIFTY100MONIFTY500MONQ50MOPSEMOQUALITYMOREALTYMOSERVICEMOSILVERMOSMALL250MOTILALOFSMOTOURMOVALUEFinancial ServicesHealthcare